Research analysts at William Blair cut their Q4 2025 earnings estimates for Fortrea in a research report issued to clients ...

Discover how FTRE's $7.7B backlog, CRO market growth, and focus on high-margin areas ensure long-term growth, efficiency, and ...

Project Optimus seeks to transform how doses are selected and optimised in oncology drug development. As this initiative ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12 ...

Detailed price information for Iqvia Holdings Inc (IQV-N) from The Globe and Mail including charting and trades.

The company's backlog, which consists of anticipated future revenue from business awards, stood at $7.7 billion as of ...

Q4 2024 Earnings Call Transcript March 3, 2025 Fortrea Holdings Inc. misses on earnings expectations. Reported EPS is $0.18 ...

BofA lowered the firm’s price target on Fortrea (FTRE) to $10 from $17 and keeps an Underperform rating on the shares after a Q4 miss and FY25 ...

Baird lowered the firm’s price target on Fortrea (FTRE) to $12 from $25 and keeps a Neutral rating on the shares. The firm updated its model ...

We reduced our fair value estimate to $15.50 per share from $27.20 to account for greater headwinds as a newly stand-alone company since its spinoff from Labcorp in 2023, which will weigh on revenue ...

Shares of Fortrea Holdings sank to a new low after the company said it expects revenue to drop this year. The stock fell 31% to a new all-time low of $9.55 in the first half of the trading day. The ...

What Happened? Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 18.5% in the pre-market session after ...